Cobimetinib in malignant melanoma: how to MEK an impact on long-term survival.
Administration, Oral
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Azetidines
/ pharmacology
Clinical Trials as Topic
Drug Resistance, Neoplasm
/ genetics
Humans
MAP Kinase Kinase 1
/ antagonists & inhibitors
MAP Kinase Signaling System
/ drug effects
Melanoma
/ drug therapy
Piperidines
/ pharmacology
Proto-Oncogene Proteins B-raf
/ antagonists & inhibitors
Skin Neoplasms
/ drug therapy
Survival Analysis
Time Factors
Treatment Outcome
BRAF inhibitors
MEK inhibitors
cobimetinib
melanoma
Journal
Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
pubmed:
15
1
2019
medline:
2
7
2019
entrez:
15
1
2019
Statut:
ppublish
Résumé
Approximately 50% of cutaneous melanomas harbor activating mutations of the BRAF-oncogene, making BRAF inhibitors (BRAFi) the standard treatment for this disease. However, disease responses are limited in duration mainly due to acquired resistance. Dual MAPK pathway inhibition with addition of a MEK inhibitor (MEKi) to a BRAFi improved the efficacy and tolerability compared with BRAFi alone. Cobimetinib (Cotellic
Identifiants
pubmed: 30638071
doi: 10.2217/fon-2018-0659
doi:
Substances chimiques
Azetidines
0
Piperidines
0
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
MAP Kinase Kinase 1
EC 2.7.12.2
MAP2K1 protein, human
EC 2.7.12.2
cobimetinib
ER29L26N1X
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM